TD Cowen Reiterates “Buy” Rating for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating reiterated by research analysts at TD Cowen in a report issued on Tuesday, Benzinga reports. They presently have a $135.00 price target on the healthcare product maker’s stock. TD Cowen’s price objective would indicate a potential upside of 26.38% from the company’s current price.

ABT has been the topic of several other research reports. The Goldman Sachs Group cut their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Bank of America lowered their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Stock Down 1.4%

NYSE ABT traded down $1.51 during midday trading on Tuesday, hitting $106.82. 1,593,138 shares of the company traded hands, compared to its average volume of 11,562,806. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company’s 50-day simple moving average is $104.74 and its 200-day simple moving average is $100.00. The company has a market cap of $184.83 billion, a PE ratio of 34.64, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.